SALLY SUSMAN - 25 Feb 2023 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
Susan E. Grant, by power of atty., for Sally Susman
Issuer symbol
PFE
Transactions as of
25 Feb 2023
Transactions value $
-$674,984
Form type
4
Filing time
28 Feb 2023, 16:52:54 UTC
Previous filing
24 Feb 2023
Next filing
27 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $1.67M +73K +53.59% $22.89 209K 25 Feb 2023 Direct F1
transaction PFE Common Stock Tax liability -$936K -22.4K -10.71% $41.75 187K 25 Feb 2023 Direct F2, F3
transaction PFE Common Stock Tax liability -$1.41M -32.5K -17.38% $43.44 154K 25 Feb 2023 Direct F4, F5
holding PFE Common Stock 772 25 Feb 2023 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -73K -100% $0.00* 0 25 Feb 2023 Common Stock 73K $22.89 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 Price is the closing price of Pfizer common stock on February 24, 2023.
F4 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.